| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Kirin Pharma Co., Ltd., CMC R & D Laboratories, Gunma, Japan,1 Kirin Pharma Co., Ltd., Production Planning, Tokyo, Japan,2 Kirin Holdings Co., Ltd., Central Laboratories for Frontier Technology, Gunma, Japan,3 Kirin Pharma Co., Ltd., Discovery Research Laboratories, Gunma, Japan,4 Daiichi Sankyo Co., Ltd., Process Technology Research Laboratories, Fukushima, Japan,5 Daiichi Sankyo Co., Ltd., Advanced Technology Research Laboratories, Tokyo, Japan,6 National Institute of Advanced Industrial Science and Technology (AIST), Ibaraki, Japan,7 Graduate School of Life and Environmental Science, University of Tsukuba, Ibaraki, Japan8
Received 14 September 2007/ Accepted 13 November 2007
When antibodies were expressed in the methylotrophic yeast Ogataea minuta, we found that abnormal O mannosylation occurred in the secreted antibody. Yeast-specific O mannosylation is initiated by the addition of mannose at serine (Ser) or threonine (Thr) residues in the endoplasmic reticulum via protein O mannosyltransferase (Pmt) activity. To suppress the addition of O-linked sugar chains on antibodies, we examined the possibility of inhibiting Pmt activity by the addition of a Pmt inhibitor during cultivation. The Pmt inhibitor was found to partially suppress the O mannosylation on the antibodies. Surprisingly, the suppression of O mannosylation was associated with an increased amount of assembled antibody (H2L2) and enhanced the antigen-binding activity of the secreted antibody. In this study, we demonstrated the expression of human antibody in O. minuta and elucidated the relationship between O mannosylation and antibody production in yeast.
Published ahead of print on 26 November 2007.
This article has been cited by other articles:
| J. Bacteriol. | Microbiol. Mol. Biol. Rev. | Eukaryot. Cell | All ASM Journals |
|---|